Current guidelines for many critical illnesses recommend targeting a MAP of 65 mm Hg, with consideration of higher MAPs in older patients with chronic HTN. Recent literature, however, suggests increased mortality in older patients who are exposed to larger quantities of vasopressor medications. In this podcast, we do a deep dive into the recently published 65 Trial, which sought to evaluate the effect of permissive hypotension in older patients with vasodilatory hypotension.
You can get CME credit for this episode here!Click here for CME Account Creation Instructions
Currently, there is no approved treatment or proven therapy for COVID-19. As such, many have turned to treatments with little to no supporting evidence....
More than 1.5 million patients undergo endotracheal intubation each year in the U.S. Endotracheal intubation can be complicated by hypoxemia, which is a known...
Bryan Hayes is back! In this podcast, we discuss pitfalls in the use of benzodiazpines along with current evidence on adjunctive treatments including propofol,...
